First Patient Dosed in Newest Stage of Study of Pexa-Vec and Chemo as Sold Tumor Fighter

First Patient Dosed in Newest Stage of Study of Pexa-Vec and Chemo as Sold Tumor Fighter
The first patient has been dosed in the Phase 2 portion of a clinical trial evaluating a combination of the cancer vaccine Pexa-Vec and chemotherapy in solid tumor patients. The dosing at the Institut Bergonié in Bordeaux, France, marks the second stage of the METROmaJX Phase 1/2 trial (NCT02630368). It will evaluate a combination of Pexa-Vec, which is produced by Transgene, and metronomic cyclophosphamide in patients with advanced soft tissue sarcoma (STS) and HER2-negative breast cancer. The French National Cancer Institute INCa is backing the study. “We are grateful to Institut Bergonié and INCa for supporting the METROmaJX trial," Maud Brandely, chief medical officer of Transgene, said in a press release. "We hope that the Phase 2 part of the study will demonstrate that this novel oncolytic virus plus chemotherapy regimen can be synergistic, resulting in a high response rate which could translate into improved overall survival. Advanced breast cancer and soft tissue sarcoma are two diseases which clearly require better treatment options for the patients.” Pexa-Vec, whose name is derived from pexastimogene devacirepvec, is an oncolytic virus designed to kill cancer cells in three ways. It triggers the breakdown of cancer cells through viral replication. It promotes disruption of blood vessels, reducing a tumo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.